[HTML][HTML] Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease
M Lodge, R Dykes, A Kennedy - Biomolecules, 2024 - mdpi.com
Elevations in fructose consumption have been reported to contribute significantly to an
increased incidence of obesity and metabolic diseases in industrial countries …
increased incidence of obesity and metabolic diseases in industrial countries …
[HTML][HTML] The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income …
RSJ Goh, B Chong, J Jayabaskaran… - The Lancet Regional …, 2024 - thelancet.com
Background Given the rapidly growing burden of cardiovascular disease (CVD) in Asia, this
study forecasts the CVD burden and associated risk factors in Asia from 2025 to 2050 …
study forecasts the CVD burden and associated risk factors in Asia from 2025 to 2050 …
Global burden of cardiovascular diseases: projections from 2025 to 2050
B Chong, J Jayabaskaran, SM Jauhari… - European Journal of …, 2024 - academic.oup.com
Aims The prediction of future trends in cardiovascular disease (CVD) mortality and their risk
factors can assist policy-makers in healthcare planning. This study aims to project geospatial …
factors can assist policy-makers in healthcare planning. This study aims to project geospatial …
[HTML][HTML] Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
There exists a complex relationship between steatotic liver disease (SLD) and
atherosclerotic cardiovascular disease (CVD). CVD is a leading cause of morbidity and …
atherosclerotic cardiovascular disease (CVD). CVD is a leading cause of morbidity and …
The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis
Aim Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are at
increased risk of incident cardiovascular disease. However, the clinical characteristics and …
increased risk of incident cardiovascular disease. However, the clinical characteristics and …
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the …
S Del Prato, Z Li, C Ramasundarahettige… - Cardiovascular …, 2024 - Springer
Aims To estimate the incidence of major adverse cardiovascular events (MACE), expanded
MACE, and MACE or Death across Fibrosis-4 score (FIB-4) categories in people with type 2 …
MACE, and MACE or Death across Fibrosis-4 score (FIB-4) categories in people with type 2 …
Knockdown of HNF1A improves type 2 diabetes combined with non-alcoholic fatty liver and glucose and lipid metabolism disorders by modulating the PI3K/AKT …
G Li, X Ji, H Gu, Q Sun, L Zhang, Z Liu, Z Qiao… - 2024 - jomh.org
Non-alcoholic fatty liver disease (NAFLD) is one abnormal buildup of fat within the liver,
independent of excessive alcohol intake. In type 2 diabetes, the presence of NAFLD can …
independent of excessive alcohol intake. In type 2 diabetes, the presence of NAFLD can …